Clinical trials: Sorafenib
Hepatocellular Carcinoma
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Phase 1 Evaluate the safety and tolerability of RAD001 in combination with sorafenib in patients with advance hepatocellular cancer (HCC) and to determine the maximum tolerated dose (MTD) Phase 2 To estimate the treatment effect…
- Trial name
- NCT00828594
- Testing
- RAD001, RAD001, sorafenib
- Where
- 8 sites in United States, Netherlands and 3 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
The purpose of this study is to: 1. To elucidate the mechanism involved in the sorafenib-induced hypophosphatemia and possible early effect of hypophosphatemia on bone mineral density 2.
- Trial name
- NCT00622479
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
The purpose of this study is to determine whether brivanib is an effective treatment for liver cancer in Asian patients who have failed or could not tolerate sorafenib therapy.
- Trial name
- BRISK-APS (NCT01108705)
- Testing
- Brivanib
- Where
- 32 sites in China, Singapore and 2 more
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Carcinoma, Hepatocellular
A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.
- Trial name
- NCT01171651
- Testing
- JX-594, Sorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Jennerex Biotherapeutics
Liver Cancer
A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.
- Trial name
- JET-HCC (NCT02029157)
- Testing
- ARQ197
- Where
- Japan
- Volunteers
- 386 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Carcinoma, Renal Cell
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people.
- Trial name
- NCT00352859
- Testing
- Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon, Gemcitabine or Interferon (only)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
This observational study is conducted as part of a systematic pharmacovigilance activity, to provide a population-based context for Pazopanib use outside of the clinical trial setting.
- Trial name
- NCT01446224
- Testing
- Pazopanib, Other anti-VEGFs
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.
- Trial name
- Shelter (NCT00943449)
- Testing
- 4SC-201, Sorafenib
- Where
- 15 sites in Germany, Italy
- Volunteers
- 57 people
- Sponsor
- 4SC AG
Carcinoma
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
The primary objective of the study was to define the safety profile and maximum tolerated dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy in patients with advanced, refractory solid…
- Trial name
- NCT00941863
- Testing
- Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet)
- Where
- 3 sites in United States
- Volunteers
- 158 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
- Trial name
- HCC (NCT04560894)
- Testing
- SCT-I10A, SCT510, Sorafenib 200mg
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Sinocelltech Ltd.
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
This is a efficacy and safety study of pembrolizumab (MK-3475, KEYTRUDA®) as monotherapy in participants with hepatocellular carcinoma (HCC) in two cohorts: participants with advanced HCC and with no curative option after disease…
- Trial name
- NCT02702414
- Testing
- Pembrolizumab
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
The purpose of Phase 1b of the study is to determine the maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PDn) and assess the safety, tolerability and activity of oprozomib in combination with sorafenib in…
- Trial name
- NCT02227914
- Testing
- Oprozomib, Sorafenib
- Where
- 6 sites in United States
- Sponsor
- Amgen
Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
- Trial name
- NCT01101906
- Testing
- OSI-906
- Where
- 41 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Kidney Diseases
Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006
This is a 400 mg (2 x 200 mg tablets) sorafenib single dose, open-label study being conducted to compare the pharmacokinetics of plasma and urine and safety of sorafenib in subjects with severe, moderate, and mild renal…
- Trial name
- NCT00119639
- Testing
- Sorafenib (BAY43-9006, Nexavar)
- Volunteers
- 32 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Regulatory Post Marketing Surveillance Study on Nexavar®
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
- Trial name
- NCT01012011
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Bayer
Solid Tumor
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
The proposed initial trial is a Phase I, open label study to evaluate the safety and explore efficacy of MG005 in combination with sorafenib in patients with solid tumor.
- Trial name
- NCT03406364
- Testing
- MG005
- Where
- Taiwan
- Volunteers
- 17 people
- Sponsor
- Metagone Biotech Inc.